A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD
Public ClinicalTrials.gov record NCT06545500. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIb, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a randomized, double-blind, placebo-controlled complete block cross-over study designed to assess the efficacy, safety, and pharmacokinetics of 3 dose levels of glycopyrrolate inhalation solution delivered twice daily via standard jet nebulizer over three 1-week active treatment periods and one 1-week placebo period in subjects with chronic obstructive pulmonary disease (COPD).
Study identification
- NCT ID
- NCT06545500
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- Industry
- Enrollment
- 46 participants
Conditions and interventions
Conditions
Interventions
- Glycopyrrolate (85 μg) Drug
- Glycopyrrolate (42.5 μg) Drug
- Glycopyrrolate (14 μg) Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 16, 2024 (Actual)
- Primary completion
- Jan 2, 2025 (Actual)
- Completion
- Jan 8, 2025 (Actual)
- Last update posted
- Feb 9, 2026
2024 – 2025
United States locations
- U.S. sites
- 7
- U.S. states
- 4
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Research of West Florida Inc - Clearwater | Clearwater | Florida | 33765 | — |
| Clinical Research of West Florida Inc - Tampa | Tampa | Florida | 33606 | — |
| Midwest Chest Consultants PC | Saint Charles | Missouri | 63301 | — |
| American Health Research Inc | Charlotte | North Carolina | 28277 | — |
| Velocity Clinical Research - Greenville | Greenville | South Carolina | 29615 | — |
| Velocity Clinical Research - Spartanburg | Spartanburg | South Carolina | 29303 | — |
| Velocity Clinical Research - Union | Union | South Carolina | 29379 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06545500, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 9, 2026 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06545500 live on ClinicalTrials.gov.